

Resource Summary Report

Generated by NIF on Sep 1, 2026

Phospho-Akt (Ser473) Antibody

RRID:AB_329825

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9271, RRID:AB_329825

Antibody Information

URL: http://antibodyregistry.org/AB_329825

Proper Citation: Cell Signaling Technology Cat# 9271, RRID:AB_329825

Target Antigen: Phospho-Akt (Ser473)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IF-IC, F

Consolidation on 7/2016: AB_329826.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:TRUE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-Akt (Ser473) Antibody

Description: This polyclonal targets Phospho-Akt (Ser473)

Target Organism: drosophilaarthropod, rat, hamster, porcine, canine, horse, mouse, bovine, human

Antibody ID: AB_329825

Vendor: Cell Signaling Technology

Catalog Number: 9271

Alternative Catalog Numbers: 9271L, NYUIHC-310, 9271S

Record Creation Time: 20250820T041739+0000

Record Last Update: 20250820T183455+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:TRUE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-Akt (Ser473) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 635 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

An P, et al. (2026) Repression of Polycomb Group Factor 1 Inhibits EMT Progression in Colon Cancers Cells via Wnt/?-Catenin and PI3K/Akt/mTOR Signaling Pathway. Digestive diseases and sciences.

Nguyen TT, et al. (2026) NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors. Molecular cancer therapeutics, 25(8), 1231.

Kishida C, et al. (2026) Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy. Journal of the Endocrine Society, 10(2), bvaf171.

Liao F, et al. (2026) Streptococcus anginosus-generated succinate promotes the progression of gastric cancer via the succinate/SUCNR1/ABRAXAS1 axis. Cell reports, 45(3), 117047.

Wenger A, et al. (2026) High-Fat Diet and a High Amyloid Load Interact to Induce PKC-? Dependent Synaptic Insulin Resistance. Molecular & cellular proteomics : MCP, 25(4), 101537.

Hang JF, et al. (2026) Out-of-frame CBX3::ALK fusion drives ALK activation and therapy response. Cell reports. Medicine, 7(4), 102697.

Chen W, et al. (2026) Insulin-like growth factor signaling regulates zebrafish lymphatic-vessel development. Cell reports, 45(2), 116971.

Caldwell BA, et al. (2026) Docosahexaenoic acid supplementation inhibits monocyte exhaustion memory formation during sepsis. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 75(1), 40.

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. *Cancer cell*, 44(6), 1218.

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. *EMBO molecular medicine*, 18(6), 2322.

Cen HH, et al. (2026) Insulin receptor trafficking and interactions in muscle cells. *Journal of the Endocrine Society*, 10(4), bvag020.

Khairkhah N, et al. (2026) Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG). *Neoplasia (New York, N.Y.)*, 73, 101278.

Blanco-Casoliva L, et al. (2026) Thrombospondin-4 is upregulated in abdominal aortic aneurysm: A vasoprotective response with potential therapeutic relevance. *British journal of pharmacology*, 183(12), 3321.

Abd El-Salam M, et al. (2026) Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway. *Translational oncology*, 67, 102753.

Han S, et al. (2026) Celecoxib potentiates ribociclib-induced apoptosis and anti-tumor activity by co-targeting COX-2/NF- κ B and PI3K/AKT/mTOR pathways in hormone receptor-positive/HER2-negative breast cancer. *Apoptosis : an international journal on programmed cell death*, 31(5).

Zhu W, et al. (2026) Phosphoproteomics identifies Rho-kinase-associated phospho-signaling and autophagy-associated alterations in the medial prefrontal cortex of a schizophrenia-related mouse model. *Pharmacological research*, 228, 108201.

Sajan MP, et al. (2026) Progranulin deficiency in the brain activates an insulin signaling pathway that may promote neurodegeneration. *iScience*, 29(5), 115720.

McCarthy E, et al. (2026) The impact of cannabidiol (CBD) in hyperglycemic zebrafish (*Danio rerio*). *PloS one*, 21(5), e0348975.

Torosyan H, et al. (2026) Structures of the PI3K γ /KRas complex on lipid bilayers reveal molecular mechanisms of PI3K γ activation. *Molecular cell*, 86(14), 2858.

Gilbert AE, et al. (2026) Mtg16/Eto2 tumor suppressor maintains and establishes repression by distinct mechanisms. *Molecular cell*, 86(13), 2492.